3DCRT联合化疗对非早期食管癌患者疗效、安全性及SF-36、KPS评分的影响

Effects of 3DCRT Combined with Chemotherapy on Efficacy, Safety, SF-36 and KPS Scores in Patients with Non-early Esophageal Cancer

目的:研究三维适形放疗(3DCRT)联合化疗对非早期食管癌患者疗效、安全性及健康调查简表(SF-36)、Karnofsky功能状态评分标准(KPS)评分的影响。方法:将医院从2018年3月-2020年3月收治的90例非早期食管癌患者纳入研究,将其以随机数字表法分为联合组和化疗组,每组45例。化疗组实施常规治疗以及DF化疗方案治疗,联合组则于化疗组的基础上增用3DCRT治疗。分析两组临床疗效、毒副反应发生情况、治疗前后SF-36、KPS评分变化情况。结果:联合组总有效率高于化疗组(P<0.05)。联合组血小板下降和放射性肺炎、白细胞下降以及放射性食管炎发生率均低于化疗组(P<0.05)。治疗前,两组SF-36各项评分及KPS评分比较,差异均无统计学意义(P>0.05);治疗后,联合组SF-36各项评分及KPS评分均高于化疗组,差异均有统计学意义(P<0.05)。结论:3DCRT联合化疗对非早期食管癌患者疗效较佳,且安全性较高,可显著改善患者的生存质量。

Objective:To study the effects of 3DCRT combined with chemotherapy on efficacy,safety and health survey brief form (SF-36) and Karnofsky functional status (KPS) score in patients with non-early esophageal cancer.Method:A total of 90 patients with non-early esophageal cancer admitted to our hospital from March 2018 to March 2020 were included in the study,they were divided into combination group and chemotherapy group by random number table method,45 cases in each group.The chemotherapy group was treated with conventional therapy and DF chemotherapy regimen,while the combination group was treated with 3DCRT in addition to the chemotherapy group.The clinical efficacy,occurrence of toxic and side effects,changes of SF-36 and KPS scores before and after treatment were analyzed.Result:The total effective rate in combination group was higher than that of the chemotherapy group (P<0.05).The incidences of thrombocytopenia,radiation pneumonia,leukopenia and radiation esophagitis in combination group were lower than those of the chemotherapy group (P<0.05).Before treatment,there were no statistically significant differences in SF-36 scores and KPS scores between the two groups (P>0.05);after treatment,SF-36 scores and KPS scores in the combined group were higher than those in the chemotherapy group,with statistical significance (P<0.05).Conclusion:3DCRT combined with chemotherapy has a good efficacy and high safety in patients with non-early esophageal cancer,which can significantly improve the quality of life of patients.